Sandoz Initiates Two More Phase III Biosimilar Trials, Reinforcing Long-term ... VAdvert Press Center (press release) Ameet Mallik, global head of Sandoz Biopharmaceuticals, added: “The start of these two studies represents significant progress for our broad ongoing development program, which includes previously announced late-stage trials for biosimilar rituximab ... |
